NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 1.841

+19.9%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Savant	7/21/2025 11:38:47 AM
	of 12871

Another claim by a company that can 'cure anything'... NNVC - BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promising results for NV-387, its lead drug candidate, in treating Measles. In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%—from 7.4 to 17 days—with no observed toxicity and dose-dependent efficacy. The drug mimics human cell features to bind and neutralize viruses, targeting over 90% of human pathogens. With global Measles cases surging and vaccine coverage declining, the Company emphasized the urgent need for a therapeutic option. “NV-387 is on its way to become the very first drug to treat Measles,” said Anil R. Diwan, PhD. NNVC - BioMedNewsBreaks - NanoViricides (NYSE American:...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext